Immune landscape and immunotherapy response in patients with relapsed/refractory AML with and without TP53 mutations and/or 17p abnormalities. (A) Heat-map of immune cell type-specific scores and biological activity scores in patients with relapsed/refractory AML treated with flotetuzumab immunotherapy. ClustVis, an online tool for clustering of multivariate data, was used for data analysis and visualization.⁴⁷  (B) Waterfall plot depicting changes in BM blasts after cycle 1 of flotetuzumab in patients with TP53 mutations and/or 17p deletion (n = 14; a BM sample was not available in 1 patient who progressed on treatment. (C) Response to flotetuzumab in relation to TP53 abnormalities (χ² test). (D) Swimmer plot showing time on treatment and time to death and/or censoring in relation to clinical response in the 15 patients with TP53 mutations and/or 17p deletion with genomic loss of TP53. Response criteria are described in "Materials and methods." (E) TIS, inflammatory chemokine, Treg cell, CD8, IFN-γ, PD1, PD-L1, and exhaustion mRNA scores in baseline BM samples from patients with TP53 mutations and/or 17p deletion. Complete responses were defined as either CR, CR with partial hematological recovery, CRi, or MLFS. Data were compared using the Mann-Whitney U test for unpaired determinations. CR, complete remission; CRh, complete remission with partial hematopoietic recovery; FU, follow-up; OB, other benefit (>30% decrease of BM blasts relative to baseline); NR, no response; PD, progressive disease; SD, stable disease.